Enteris BioPharma Announces Acceptance of Two Abstracts for Presentation at ENDO 2022 Annual Conference

Rhea-AI Summary

On April 12, 2022, Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), announced acceptance of two abstracts for poster presentations at ENDO 2022, scheduled for June 11-14, 2022, in Atlanta. The abstracts focus on oral leuprolide formulations developed using Enteris' Peptelligence® technology, aimed at improving patient compliance for therapies typically requiring injections. These represent significant advancements in Enteris' clinical pipeline targeting critical unmet needs in treatment.

Positive

• Acceptance of two abstracts for presentation at ENDO 2022 indicating progress in Enteris' clinical development.
• Focus on oral leuprolide formulation enhances patient compliance and addresses significant treatment gaps.

Negative

• None.

BOONTON, N.J., April 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that two submitted abstracts were accepted for poster presentations at the 104^th annual meeting of The Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, Georgia.  The abstracts highlight research into oral formulations of leuprolide developed utilizing Enteris' proprietary Peptelligence® platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class III and IV small molecules.

"We are very pleased to report that results from two of our clinical studies involving leuprolide will be the subject of presentations at ENDO 2022," stated Gary Shangold, M.D., Chief Medical Officer for Enteris BioPharma.  "Oral leuprolide represents Enteris' most clinically advanced internal product candidate and underscores the company's rapidly advancing clinical development pipeline targeting underserved patient populations where oral delivery can enable competitive and patient compliance advantages. We are working to develop the product to address diseases in which gonadotropin-releasing hormone (GnRH) agonists are known to provide benefit and for which an oral format can improve patient compliance."

The titles of the abstracts are as follows:

Title:	Systemic Delivery of Leuprolide via Oral Administration
Authors:	Gary A. Shangold M.D., Arkady Rubin Ph.D., Thomas Daggs, John Vrettos Ph.D., Andrejs Rasums, Angelo Consalvo, Nicola Skeet, Paul Shields Ph.D.
Title:	Effective Suppression of Gonadotropins and Gonadal Steroids Following Oral Administration of Leuprolide
Authors:	Gary A. Shangold M.D., Arkady Rubin Ph.D., Thomas Daggs, John Vrettos Ph.D., Andrejs Rasums, Angelo Consalvo, Nicola Skeet, Paul Shields

The full poster presentations will be on display during the conference in ENDO 2022's virtual poster hall starting on June 11, at 10:00 a.m. ET. Information about ENDO 2022 may be accessed at https://endo2022.endocrine.org/Home.

About Enteris BioPharma
Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated contract development and manufacturing (CDMO) services including innovative formulation solutions utilizing its proprietary drug delivery technologies, Peptelligence® and ProPerma®. The technologies have been the subject of numerous feasibility studies and active development programs, several of which are in clinical development. Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of drug products that address significant unmet clinical needs for which there is no satisfactory treatment option. For more information on Enteris BioPharma and its proprietary oral drug delivery technologies, please visit http://www.EnterisBioPharma.com.

View original content:https://www.prnewswire.com/news-releases/enteris-biopharma-announces-acceptance-of-two-abstracts-for-presentation-at-endo-2022-annual-conference-301523123.html

SOURCE Enteris BioPharma, Inc.

FAQ

What abstracts did Enteris BioPharma submit for ENDO 2022?

Enteris BioPharma submitted two abstracts focusing on oral formulations of leuprolide.

When is ENDO 2022 taking place?

ENDO 2022 will be held from June 11-14, 2022.

What is the significance of the leuprolide presentations at ENDO 2022?

The presentations highlight advancements in oral drug delivery technologies which could enhance patient compliance.

What company is behind Enteris BioPharma?

Enteris BioPharma is a wholly-owned subsidiary of SWK Holdings Corporation.

What is the Peptelligence technology?

Peptelligence is Enteris' proprietary platform for oral drug delivery of peptides and small molecules.